New antibody drug aims to stop deadly virus after transplant
NCT ID NCT07261215
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 21 times
Summary
This study tests a new medicine called zuberitamab for people who develop an EBV infection after a stem cell transplant. EBV can cause a serious condition called PTLD, which can be fatal if not treated. The drug targets infected cells to clear the virus and prevent complications. About 20 adults who have had a stem cell transplant and test positive for EBV will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.